Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating cancer treatments for diseases where current medical options are insufficient. Its clinical-stage portfolio features zilovertamab, a humanized monoclonal antibody designed to bind to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule that works by inhibiting the biological activity of ETS-family transcription factor oncoproteins. Additionally, Oncternal is advancing ONCT-808, a chimeric antigen receptor T-cell (CAR-T) therapy candidate also targeting ROR1, as well as ONCT-534, a dual-action androgen receptor inhibitor aimed at treating castration-resistant prostate cancer and other cancers driven by androgen receptors.